Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant for Breakthrough CINV
NCT01031953Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2008
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Improvement in Nausea Score From Baseline to 2 Hours as Assessed by the Numerical Visual Analogue Scale. Started Aug 2008; status: terminated.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01031953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031953.